Benjamin Machinas Beneski

ALLO

SVP, CHIEF TECHNICAL OFFICER · ALLOGENE THERAPEUTICS, INC. · CIK 0002057918

FILING MIX · LIFETIME40%/60%

BUYS

SELLS

TOTAL VALUE

$62.5K

COMPANIES

ACTIVE SINCE

Mar 2025

HOLDINGS NOW

195,338

AVG SELL PX

$2.18

Trades · vs SPY

Loading price series…

Performance · forward returns vs SPY

6 backtested trades · 8 horizons · 15 pending

Forward-return performance of every backtestable P/S trade by Benjamin Machinas Beneski, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.

HORIZON	TRADES	WIN RATE	INSIDER RETURN	SPY RETURN	MEAN EXCESS	MEDIAN EXCESS	T-STAT
7d	6	+50.00%	-2.44%	-0.18%	-2.26%	-1.22%	—
14d	6	+66.67%	-2.79%	-0.31%	-2.47%	-4.44%	—
30d	6	+66.67%	-0.45%	+1.01%	-1.46%	-7.27%	—
60d	6	+66.67%	-2.70%	+3.75%	-4.77%	-20.58%	—
90d	6	+66.67%	-2.27%	+7.25%	-6.34%	-24.80%	—
180d	6(4 pending)	+50.00%	+18.24%	+13.87%	+4.37%	+4.37%	—
1y	6(5 pending)	+0.00%	+23.71%	+18.03%	+5.68%	+5.68%	—
2y	6(6 pending)	—	—	—	—	—	—

How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.

Holdings over time

ALLO · 195,338 shares · as of Mar 31, 2026

Trading cadence · quarterly flow

BUY ● SELL ●

2025

2026

FLOW · 4 buys / 6 sellsCOVERAGE · 5 quarters

Form 4 filings · all activity

COMPANY	TYPE	SHARES	PRICE	VALUE	HELD AFTER	TRADE DATE	FILED	DETAILS
ALLO ALLOGENE THERAPEUTICS, INC.	SALE SVP, Chief Technical Officer	2,867	$2.50	$7.2K	195,338	Mar 31, 2026	Apr 2, 2026 ↗	View →
ALLO ALLOGENE THERAPEUTICS, INC.	SALE SVP, Chief Technical Officer	4,835	$2.47	$11.9K	198,205	Mar 16, 2026	Mar 18, 2026 ↗	View →
ALLO ALLOGENE THERAPEUTICS, INC.	SALE SVP, Chief Technical Officer	7,132	$2.60	$18.5K	203,040	Mar 2, 2026	Mar 4, 2026 ↗	View →
ALLO ALLOGENE THERAPEUTICS, INC.	SALE SVP, Chief Technical Officer	7,549	$1.73	$13.1K	210,172	Feb 2, 2026	Feb 4, 2026 ↗	View →
ALLO ALLOGENE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	105,720	—	—	105,720	Feb 2, 2026	Feb 4, 2026 ↗	View →
ALLO ALLOGENE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	373,757	—	—	373,757	Feb 2, 2026	Feb 4, 2026 ↗	View →
ALLO ALLOGENE THERAPEUTICS, INC.	SALE SVP, Chief Technical Officer	786	$1.22	$959	217,721	Nov 17, 2025	Nov 19, 2025 ↗	View →
ALLO ALLOGENE THERAPEUTICS, INC.	SALE SVP, Chief Technical Officer	5,488	$1.98	$10.8K	218,507	Mar 14, 2025	Mar 18, 2025 ↗	View →
ALLO ALLOGENE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	112,339	—	—	112,339	Mar 1, 2025	Mar 5, 2025 ↗	View →
ALLO ALLOGENE THERAPEUTICS, INC.	PURCHASEGRANT Stock grant	31,755	—	—	223,995	Mar 1, 2025	Mar 5, 2025 ↗	View →

Other insiders · ALLO

Loading peer insiders…

About this filer

CIK 0002057918

ROLE

SVP, Chief Technical Officer

PRIMARY

ALLO

COMPANIES

ACTIVE SINCE

Mar 2025

MARKETPEEL · /INSIDER/0002057918DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE

Benjamin Machinas Beneski

The morning brief, before the bell.